Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 10/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | KAT2A | Q92830 | 2/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830799 | 0.95 | ALDH1A1 (0.35) | ALDH1A1P2RX3KDM4E | |
| SCHEMBL17830794 | 0.93 | CCKBR (0.38) | ALDH1A1KAT2BKDM4E | |
| SCHEMBL17830798 | 0.92 | MEN1 (0.37) | ALDH1A1P2RX3KAT2BKDM4E | |
| SCHEMBL17830801 | 0.92 | HSP90AA1 (0.37) | ALDH1A1P2RX3FFAR1FFAR4 | |
| SCHEMBL17830802 | 0.90 | MDM2 (0.34) | ALDH1A1P2RX3FFAR4KDM4E | |
| SCHEMBL17830803 | 0.87 | PTPN7 (0.35) | ALDH1A1P2RX3KAT2BKDM4E | |
| SCHEMBL17830795 | 0.84 | ALDH1A1 (0.38) | ALDH1A1KDM4E | |
| SCHEMBL17830796 | 0.83 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL17830793 | 0.83 | PARK7 (0.37) | ALDH1A1KAT2B | |
| SCHEMBL17830800 | 0.81 | RECQL (0.36) | ALDH1A1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | CORNELL UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166549-A1 | BCL6 INHIBITORS AS ANTICANCER AGENTS | BCL6, BCL6B, BAZ2A | ALDH1A1 4832/4885P2RX3 4858/4885FFAR1 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.